Abstract 251P
Background
According to data of Globocan 2018 year, 18.1 million of new cancer cases have been registered and more than half of these cases occur in the Asian continent. Moreover, among women, cervical cancer takes the 4th place in morbidity and mortality. In the Republic of Uzbekistan cervical cancer takes third place among all cancers. Thus, remaining one of the frequent oncogynecological pathology, cervical cancer is a serious public health problem both in the world and in Uzbekistan.
Methods
To analyze condition of morbidity and mortality of cervical cancer we studied the state report -Information on diseases of malignant neoplasms.
Results
The average age of patients with cervical cancer was 61.3 in 2009 y, and 58.3 in 2019y. In 2009 y, the incidence rate per 100,000 population was 4.6, and in 2019 y this indicator increased to 5.6. Moreover, the highest incidence rate per 100,000 population in 2009 was observed in the Republic of Karakalpakstan, Tashkent city, Namangan, Andijan and Khorezm regions with indicators of 7.3; 7.0; 6.3; 5.8 and 5.7 per 100,000 population respectively, and the lowest in Surkhandarya (2.2), Kashkadarya (2.8) and Jizzakh (3.2) regions. In comparison of 2019 y, the highest incidence rate per 100,000 population was in Tashkent, the Republic of Karakalpakstan, Namangan and Khorezm regions with indicators of 11.8; 7.3; 6.8 and 6.5, respectively, and the lowest was observed in Kashkadarya (4.3), Samarkand (3.7) and Surkhandarya (2.8) regions. According to mortality rates, it was showed that there was growth of this indicator from 2.0 per 100,000 population in 2009 y to 3.0 per 100,000 population in 2019 y. Relatively high mortality rate per 100,000 population in 2009 y was observed in Tashkent (4.2), Khorezm (3.4) and Tashkent (2.9) regions, and in 2019 in the Republic of Karakalpakistan, Namangan and Khorezm regions with indicators of 5.8; 5.1 and 4.8, respectively.
Conclusions
In conclusion it can be shown that cervical cancer has a tendency to increase both morbidity and mortality in the Republic of Uzbekistan. The increase in morbidity is due to the intensive work of primary medical care, implementation of modern diagnostic methods, creation and use of diagnostic and treatment standards, and screening programs.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
325P - Clinical characteristics and outcomes of cancer patients with COVID-19 infection: A retrospective study in a single center in the Philippines
Presenter: Frances Victoria Que
Session: e-Poster Display Session
326P - Management of diffuse large B cell lymphomas in the COVID-19 era
Presenter: David Ng
Session: e-Poster Display Session
327P - COVID-19 in patients with oncohematologic diseases in Kazakhstan
Presenter: Zaure Dushimova
Session: e-Poster Display Session
328P - Impact of COVID-19 pandemic on 30 days colorectal cancer patients mortality undergoing emergency operation
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
329P - Radiotherapy palliative and COVID-19: Experience of radiotherapy oncology department of Cancer Center Tlemcen, Algeria
Presenter: Asma Mous
Session: e-Poster Display Session
330P - COVID and cancer: Choosing between hammer and anvil
Presenter: Ullas Batra
Session: e-Poster Display Session
331P - The clock stopped with COVID-19 but continued ticking for cancer patients
Presenter: Sasi Shanmugam Senga
Session: e-Poster Display Session
336P - Efficacy of methylcobalamin administered intravenously for chemotherapy-induced peripheral neuropathy (CIPN): A prospective crossover study
Presenter: Jun Chen
Session: e-Poster Display Session
337P - A prospective study about the quality of life and chemotherapy-induced peripheral neuropathy
Presenter: Wala Ben Kridis
Session: e-Poster Display Session
338P - Vitamin E in the treatment of chemotherapy and radiation-induced mucositis: A meta-analysis of randomized controlled trials
Presenter: Michelle Joane Alcantara
Session: e-Poster Display Session